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A B S T R A C T   
It is unclear if surveillance for postmenopausal women with medically inoperable stage 1 endometrial cancer 
(EC) should differ depending on their management strategy. Thus, we investigated the utility of surveillance 
endometrial sampling among 53 postmenopausal women with medically inoperable, clinical stage I, grade 1 
endometrioid EC who received either progestin therapy or radiation between 2009 and 2018, at a single aca-
demic institution. Frequency and results of endometrial sampling, as well as recurrence and survival rates were 
studied. Of 53 patients, 18 (34.0%) received progestin therapy and 35 (66.0%) radiation. Medically managed 
patients were treated with megestrol acetate (27.7%), a levonorgestrel intrauterine device (27.7%), or both 
(44.4%). Radiated patients were mostly treated with high-dose rate brachytherapy only (77.1%). Surveillance 
endometrial sampling (median procedures = 4, range 1–10) was strictly adhered to among all patients who 
received progestin therapy, but infrequently (6/35, 17.1%) performed among radiated patients, yielding no 
positive results. Three recurrences occurred over the median follow-up of 38 months. Two (11%) women in the 
progestin therapy group recurred locally and were diagnosed by endometrial sampling. One (3%) patient in the 
radiation group recurred distally in the lung 25.3 months after completing brachytherapy. We conclude that 
appropriate surveillance for women with medically inoperable, clinical stage I, grade 1 EC depends on the 
management strategy. For those treated with progestins, surveillance with endometrial sampling every 3–6 
months can reveal local recurrence. However, given the excellent local control after radiation, endometrial 
sampling may not be warranted for women treated with definitive radiation.   
1. Introduction 
While incidence rates for many cancers are decreasing, endometrial 
cancer (EC) has risen over 1% each year resulting in 11,000 deaths 
annually (National Cancer Institute, 2018). The current standard of care 
for early stage EC is hysterectomy with surgical staging. However, 10% 
of patients with newly diagnosed EC are not surgical candidates 
(Network NCC, 2018). Medical management with progestin therapy and 
definitive radiation therapy (RT) have been validated as nonsurgical 
treatment options for medically inoperable patients, but risks for 
recurrence, cancer-specific mortality, and overall mortality are poorly 
understood, leaving clinicians with little evidence to guide surveillance 
in this patient population (Network NCC, 2018). 
The goal of surveillance is to identify recurrence before symptoms 
occur, when interventions may improve quality or duration of life. Thus, 
the disparate recurrence rates that clinical stage I EC patients face based 
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on their treatment(s) (progestin therapy – 20%; RT – 18% vs. hyster-
ectomy – 5%) (Baker et al., 2012; Podzielinski et al., 2012; Sasada et al., 
2018; Acharya et al., 2016) suggests that endometrial sampling should 
be tailored to their management strategy. Unfortunately, there is limited 
published data to support development of evidence-based guidelines on 
the role of endometrial sampling during surveillance exams for post-
menopausal women with medically inoperable, clinical stage I EC. 
Recommendations for this vulnerable population were not included in 
the Society of Gynecologic Oncology (SGO) position statement on post- 
treatment surveillance and diagnosis of recurrence in women with gy-
necologic malignancies (Salani et al., 2017). The National Comprehen-
sive Cancer Network provides general guidance for surveillance for all 
EC survivors without distinguishing differences based on recurrence risk 
or patterns of recurrence (Network NCC, 2018). The one exception is the 
algorithm on women who meet criteria for fertility-sparing management 
of their EC. Though one may extrapolate and apply these recommen-
dations to postmenopausal, medically inoperable women who undergo 
progestin therapy or RT, the role of surveillance endometrial sampling in 
this population is unclear. 
Our objectives were two-fold. First, we set out to describe how 
endometrial sampling is utilized by gynecologic oncologists during 
surveillance for postmenopausal, medically inoperable stage I grade 1 
EC patients. Second, we aimed to describe recurrence patterns among 
those who responded to initial treatment with progestin therapy or 
definitive RT. 
2. Methods 
We conducted a single institution case series of our experience with 
endometrial sampling for surveillance of recurrence in patients with 
medically inoperable, clinical stage I grade 1 endometrioid EC. All 
surveillance exams were performed by faculty or fellows within the 
Division of Gynecologic Oncology at Washington University School of 
Medicine. Individualized risk assessments for perioperative morbidity 
and mortality were performed by the treating gynecologic oncologist 
and patients were deemed medically inoperable if these risks out-
weighed the benefit of surgical staging. Before initiation of our study, all 
investigations were reviewed and approved by Washington University’s 
Human Research Protection Office (IRB #201903117). 
We identified postmenopausal women diagnosed with clinical stage I 
grade 1 endometrioid EC between 2009 and 2018, and did not undergo 
primary surgery for treatment of their cancer. Patients were identified 
by ICD-9 or ICD-10 procedure code(s) for endometrial biopsy and/or 
dilation and curettage. Endometrial sampling method (eg, number of 
passes or sample amount) was not standardized. Central pathology was 
performed by subspecialized gynecologic pathologist. Patients with 
grade 2 or 3 endometrioid EC or mixed malignancy were excluded. We 
also excluded patients who were deemed medically inoperable at time of 
their cancer diagnosis, but whose perioperative risk factors improved 
and they ultimately underwent hysterectomy. All patients in our case 
series underwent either progestin therapy or received RT at the Radia-
tion Oncology Center Mallinckrodt Institute of Radiology at Washington 
University. Patients referred for definitive RT underwent axial imaging 
with pelvic magnetic resonance imaging (MRI) or computed tomogra-
phy (CT) and were treated with high-dose rate (HDR) brachytherapy ±
pelvic external beam RT for those with evidence of deep myometrial 
invasion. Patients (n = 2) who initially received progestin therapy for 
their EC and then underwent salvage RT for either refractory or recur-
rent carcinoma were classified under the progestin therapy group. 
Records were reviewed for demographic information, medical 
comorbidities, pathology, number and results of surveillance endome-
trial biopsies, as well as recurrence and survival rates. Recurrence was 
based on pathologic diagnosis of endometrial adenocarcinoma or im-
aging. Patients were followed from time of diagnosis until loss to follow- 
up, death, or time of analysis. The primary outcome was number of 
surveillance endometrial sampling and the incidence of positive results. 
Secondary outcomes included recurrence patterns and survival out-
comes. Differences between treatment groups were compared using χ2 
test, Fisher’s exact tests or Student’s t test as appropriate. A p-value of 
<0.05 was considered statistically significant. 
3. Results 
We identified 53 postmenopausal women with clinical stage I grade 
1 endometrioid EC between 2009 and 2018, who had a documented 
evaluation by their treating gynecologic oncologist stating that they 
were medically unfit to undergo surgical staging. Eighteen (34.0%) of 
these women received progestin therapy and the remaining thirty-five 
(66.0%) inoperable patients received definitive RT. There were no dif-
ferences in patient demographics based on treatment group (Table 1). 
Median body mass index was 54.1 kg/m2 (IQR 41.4–63.4) and most had 
obesity-related comorbidities such as diabetes mellitus (58.5%) and 
hypertension (86.8%). Reasons for not being surgical candidates 
included obesity (73.5%) or a cardiopulmonary diagnosis (62.2%) fol-
lowed by poor performance status (22.6%) or a recent cerebrovascular 
accident (7.5%). Fifty-one (96.2%) patients had imaging prior to treat-
ment to confirm their clinical stage—most frequently this was either by 
MRI (66.0%) or CT scan (30.2%). 
3.1. Utilization of endometrial sampling 
All patients who underwent progestin therapy had surveillance 
endometrial sampling (median procedures = 4, range 1–10). Two 
women (11.1%) were refractory to medical management, including one 
Table 1 
Patient Demographics and Clinical Characteristics.  
Variable Progestin 
Therapy 








Age (median, IQR) 61.2 (56.0, 
72.1) 
62.5 (57.8–70.1) 0.56 






5 (15.2)  






29 (96.7)  
Diabetes 10 (55.6) 21 (60.0) 0.39 
Hypertension 17 (94.4) 29 (82.9) 0.23 
BMI (kg/m2) (median, IQR) 58.5 (38.9, 
62.6) 
53.8 (41.4–63.4) 0.462 









2 (5.7)  
Alcohol user 4 (66.7) 6 (17.1) 0.81 







8 (44.4)   
Radiation   N/A 
HDR Brachytherapy + EBRT 
HDR Brachytherapy Only  
7 (20.0) 
28 (80.0)  
Brachytherapy   N/A 
Tandem and Ovoid (T&O) 





3 (8.6)  
IQR, interquartile range; BMI, body mass index; kg, kilogram; m, meters; LNG, 
levonorgestrel; IUD, intrauterine device; HDR, high-dose rate; EBRT, external 
beam radiotherapy. 
Listed as Median and interquartile ranges 
Missing values were excluded from the denominator of the percentages. 
* One patient also received concomitant letrozole. 
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who reported vaginal spotting, but otherwise was asymptomatic. Pelvic 
ultrasound was not utilized in either case and both underwent endo-
metrial biopsy which confirmed persistent grade 1 disease after 6 and 
12 months respectively. Both were salvaged with definitive HDR 
brachytherapy. With regards to the radiated cohort, only 6 (17.1%) 
patients underwent surveillance endometrial sampling (median pro-
cedures = 1, range 1–4). Of these 6 patients, 5 had endometrial samples 
that were evaluable. One patient was not able to be sampled, even under 
anesthesia with ultrasound guidance due to significant vaginal syn-
echiae. Of the 5 patients who had evaluable pathology, 3 had docu-
mentation of fibrinous or necrotic tissue, consistent with prior radiation. 
3.2. Recurrence and follow-up 
Median follow-up was 29.0 ± 26.0 months for those receiving pro-
gestin therapy compared to 28.7 ± 25.0 months after RT (P = 0.48). 
Table 2 provides a clinical summary of the 3 medically inoperable EC 
patients who recurred – 2 (11%) were treated with progestin and 1 (3%) 
with definitive RT (P = 0.22). All women who experienced recurrence in 
the progestin therapy group were asymptomatic, recurred locally, and 
were diagnosed by surveillance endometrial sampling by pipelle. The 
first patient achieved a complete response after 14 months of the levo-
norgestrel intrauterine device (LNG-IUD), but recurrence was detected 
3 months later. Her IUD was continued and her cancer resolved 3 
months later and she remains without evidence of disease. The other 
patient who failed progestin therapy had an endometrial biopsy that 
showed rare microscopic foci of endometrioid adenocarcinoma after 12 
months of LNG-IUD and megestrol acetate, and ultimately had complete 
resolution after 24 months. One year later, endometrial pipelle diag-
nosed local recurrence and she underwent salvage RT and is alive 
without disease. The one patient who recurred after definitive RT had 
lung metastasis 25.3 months after completing HDR brachytherapy. She 
received hormonal therapy for her recurrence and ultimately died of 
disease 4.2 years from her initial diagnosis. The overall mortality rate 
was 5.7% – 1 patient (1.9%) in the RT group was dead of disease and the 
remaining (N = 2, 3.8%) died due to cardiopulmonary comorbidities. 
4. Discussion 
In this study, endometrial sampling during post-treatment surveil-
lance of medically inoperable clinical staged I grade 1 EC patients is 
inconsistently utilized by gynecologic oncologists. Albeit a small case 
series, our results add value to a growing literature on medically inop-
erable patients by comparing clinical outcomes of postmenopausal 
women who received either progestin therapy or RT. Our data supports 
that appropriate surveillance for women with medically inoperable, 
clinical stage I, grade 1 EC depends on the management strategy given 
differences in local control. Given the excellent local control after RT, 
endometrial sampling may be omitted for asymptomatic women treated 
with definitive RT. However, for those treated with progestins, sur-
veillance with endometrial sampling every 3–6 months is appropriate. In 
our study, all recurrences in the progestin group were diagnosed in 
asymptomatic women and detected through surveillance endometrial 
sampling with pipelle. Whether endometrial sampling changes disease- 
specific survival, or just adds lead-time bias in this highly-comorbid 
population is an important question that remains to be addressed in a 
larger prospective trial. 
Though treatment of EC by progestin therapy is largely based on 
studies of younger women desiring future fertility, our study, along with 
others, suggests there may also be a role for progestin therapy to treat 
postmenopausal women if RT is not feasible or desired (Baker et al., 
2012; Staples et al., 2018). Macchia and colleagues reported on 9 
women aged ≥65 years treated with LNG-IUD followed by palliative 
radiation (30 Gy) and showed a high bleeding remission rate of 88.8% 
(Macchia et al., 2016). Median follow-up was 20 months, but they did 
not report recurrence or survival data. Baker et al showed complete 
response rates of 50% attained by women with either atypical endo-
metrial hyperplasia (n = 20) or grade 1 EC (n = 16) treated with LNG- 
IUD (Baker et al., 2012); yet, 4 of the 18 women who achieved a com-
plete response later relapsed. Based on their experience of few women 
(n = 1) developing bleeding with recurrence, they favored surveillance 
biopsies following response to LNG-IUD; the exception being those 
women whose goals were palliation of symptoms. 
Furthermore, Staples et al reported on 51 obese patients with stage I- 
II EC, all grades, with mean age of 66 and mean BMI of 49.0 kg/m2 
(Staples et al., 2018). Though likely underpowered, their response rates 
were notably lower for women treated with hormonal therapy compared 
to RT (38.1% vs. 63.6%, p = 0.063). This mirrors our study results, 
though we admittedly have a lower risk population. Nevertheless, both 
our study and theirs lack consistent endometrial sampling. Staples and 
colleagues disclosed that of the 25 patients who responded to initial 
treatment, 15 (60%) were deemed to have complete responses based on 
documented exams though not confirmed by biopsy. 
As our population ages and the obesity epidemic continues, 
Table 2 









































IA LNG-IUD Yes 2/8 Endometrial 
Biopsy 










No 4/6 Endometrial 
Biopsy 
















4.2 Dead of 
disease 
PS = performance status; LNG-IUD = Levonorgestrel intrauterine device; HDR = high-dose rate; brachy = brachytherapy. 
* Age at diagnosis. 
¥ Simon-Heyman capsules and tandem and ovoid. 
† This was suspected based on interval increase in size of pulmonary nodules visualized on CT scan of the chest taken 8.2 months apart. Not amenable to CT-guided 
biopsy and patient too unhealthy to undergo a video-assisted thoracoscopic surgery. 
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examining survival and recurrence outcomes among postmenopausal 
women treated with progestin therapy versus definitive RT is important. 
The median BMI of 54.1 kg/m2 in our cohort is an alarming reminder 
that effective and accessible weight management strategies for inoper-
able EC patients are likely underutilized. Progestin therapy may effec-
tively stabilize EC, but is associated with weight gain (Cholakian et al., 
2016). As obesity remains an independent predictor of mortality for 
women with EC (Calle et al., 2003) and weight loss can reverse endo-
metrial pathology (Argenta et al., 2013), further study of how to treat 
obesity while managing EC is needed. 
We acknowledge other limitations in our study related to its retro-
spective study design and small sample size. Though all patients were 
evaluated by a gynecologic oncologist and felt that perioperative risks 
outweighed the benefits of surgical staging, there remained heteroge-
neity in the definition of medically inoperable, as well as pre-treatment 
diagnostic imaging and management strategy. Consistent with other 
observational studies on medically inoperable EC patients, we 
confirmed the practical challenges of inconsistent endometrial sampling 
during surveillance visits, as well as possible sample error. Given our 
small case series, it was not feasible to match based on propensity score 
to reduce selection bias for treatment modality. Nevertheless, our data 
lend support for providers to consider patient adherence to cancer care 
follow-up when recommending treatment for medically inoperable EC 
patients. Although RT provides excellent local control, this treatment 
may be considered less feasible due to financial, social, or even physical 
constraints, not to mention patients’ emotional stress, including issues 
related to sexual health. The unique considerations to each management 
strategy must be individualized to patients’ goals of care and level of 
comfort. 
5. Conclusions 
Appropriate surveillance for women with clinical stage I grade 1, 
medically inoperable EC depends on the management strategy. RT 
provides such excellent local control that post-treatment endometrial 
sampling may be safely omitted in asymptomatic women after definitive 
RT. Secondly, patients undergoing progestin therapy were more likely to 
recur locally and should undergo surveillance with endometrial sam-
pling according to the schedule recommended by the NCCN guidelines. 
Given overall poor compliance with endometrial sampling, adherence to 
follow-up should be considered when determining initial treatment for 
patients with medically inoperable EC. A multi-centered trial is war-
ranted to assess generalizability of our findings to improve outcomes for 
this vulnerable population. 
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